

## Use of adalimumab (Humira®) within NHS Wales

# AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA125)

### NICE GUIDANCE ISSUED AUGUST 2007

(Refer to NICE website for full guidance on NICE recommendations,  
including any specific restrictions on the use of the technology)

*Please disseminate the following information to the appropriate individuals within your organisation across NHS Wales.*

Dear Colleague

The Minister for Health & Social Services has endorsed AWMSG's recommendation that:

Adalimumab (Humira®) should be available for use within NHS Wales for the treatment of psoriatic arthritis (PsA) in accordance with the licensed indication and supervised by specialist physicians experienced in the diagnosis and treatment of PsA subject to the following restriction:

Adalimumab (Humira®) is used in accordance with the current British Society of Rheumatology Guidelines for anti-TNF-alpha therapy in adults with psoriatic arthritis.

If you wish to view the appraisal meeting documentation please click on the link below.

[All Wales Medicines Strategy Group - AWMSG June 2006](#)

This information has been disseminated by the AWMSG Secretariat.

**Professor Philip A Routledge**  
**Acting Chairman AWMSG**

**2<sup>nd</sup> August 2006**

**Enquiries: please contact**

Mrs Ruth Lang  
Liaison Manager  
Welsh Medicines Partnership  
Dept Pharmacology, Therapeutics & Toxicology  
Cardiff University  
Wales College of Medicine  
Heath Park, Cardiff, CF14 4XN

Tel: 029 20745466

Website address: [www.wales.nhs.uk/awmsg/](http://www.wales.nhs.uk/awmsg/)